Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis
Sirolimus, an immunosuppressant option for kidney transplant recipients, may reduce cancer risk by interrupting the mammalian target of rapamycin pathway. However, studies of sirolimus and cancer incidence in kidney recipients have not been definitive, and have had limited ability to examine specifi...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
John Wiley & Sons, Ltd
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567030/ |